China's health authorities are set to implement a coordinated national strategy to integrate new obesity therapies, such as GLP-1 receptor agonists, into treatment guidelines, while ensuring equitable access and addressing safety monitoring. The projected surge in the use of these advanced treatments is expected to significantly reduce obesity prevalence and metabolic-associated severe health (MASH) complications, yielding benefits in cardiovascular health and economic productivity over the next five years. However, ethical concerns about drug access disparities and potential unfair advantages in competitive sports will need to be urgently addressed.
Title not available for this citation.
“Obesity, a global public health crisis driven by complex interactions of genetic, environmental, and behavioral factors, necessitates innovative therapeutic strategies.”
Title not available for this citation.
“The evolution of anti-obesity pharmacotherapy has progressed from the use of high-risk agents [...] to modern gut hormone-based therapies, notably glucagon-like peptide-1 receptor agonists (GLP-1RAs), which effectively suppress appetite.”
Title not available for this citation.
“Emerging therapeutic strategies are focusing on novel targets such as growth differentiation factor 15 (GDF15) and its specific receptor glial cell-line derived neurotrophic factor family receptor α-like (GFRAL).”
Title not available for this citation.
“This meta-analysis shows that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly increase histologic resolution of MASH without worsening fibrosis (risk ratio 2.96; 95% CI 1.70-5.15, p <0.001).”
Title not available for this citation.
“GLP-1 RAs significantly increase histologic resolution of MASH without worsening fibrosis and improve fibrosis stage without worsening MASH (risk ratio 1.59; 95% CI 1.32-1.90, p <0.001).”
Title not available for this citation.
“In vitro, LY3537021 demonstrated potency greater than native GIP and selectivity for the GIPR.”
Title not available for this citation.
“In vivo in rats, chronic treatment with LY3537021 resulted in weight loss and improved glycemic control during a glucose tolerance test.”
Title not available for this citation.
“For example, participants with T2D treated with 25 mg of LY3537021 lost a mean of 3.14 kg of body weight compared with 0.36 kg in the placebo group (p < 0.05) at day 57.”
Title not available for this citation.
“LY3537021 was well tolerated with infrequent gastrointestinal adverse events.”
Title not available for this citation.
“Our findings demonstrated that GLP-1RAs (semaglutide) have potential therapeutic effects on obesity-induced reproductive dysfunctions by modulating the interplay mechanisms of inflammation and metabolic dysregulation via the SIRT-associated pathway.”
Title not available for this citation.
“Adiposity and metabolic dysregulation, mainly insulin resistance and IRS1 disruption, were observed in the obese group.”
Title not available for this citation.
“The prevalence of overweight and obesity in China has continued to increase over the last decade, with mounting health and economic consequences.”